IÃ'aki Gutierrez-Ibarluzea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4349678/publications.pdf

Version: 2024-02-01

78 papers

1,138 citations

394421 19 h-index 434195 31 g-index

91 all docs 91 docs citations

91 times ranked 1526 citing authors

#	Article	IF	Citations
1	CT or Invasive Coronary Angiography in Stable Chest Pain. New England Journal of Medicine, 2022, 386, 1591-1602.	27.0	144
2	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	5.5	81
3	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	3.5	75
4	Nutrition economics – characterising the economic and health impact of nutrition. British Journal of Nutrition, 2011, 105, 157-166.	2.3	49
5	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Frontiers in Pharmacology, 2014, 5, 109.	3.5	44
6	Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?. BMC Cancer, 2017, 17, 577.	2.6	39
7	Health economics and nutrition: a review of published evidence. Nutrition Reviews, 2012, 70, 693-708.	5.8	38
8	Guiding the process of health technology disinvestment. Health Policy, 2010, 98, 218-226.	3.0	37
9	Commentary: Europe needs a central, transparent, and evidence based regulation process for devices. BMJ, The, 2013, 346, f2771-f2771.	6.0	33
10	Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. European Radiology, 2017, 27, 2957-2968.	4.5	33
11	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2017, 33, 279-287.	0.5	32
12	Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. Journal of Gastroenterology, 2012, 47, 359-365.	5.1	31
13	Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World Journal of Gastroenterology, 2017, 23, 2731.	3.3	29
14	Percentage incidence of \hat{I}^3 -aminobutyric acid neurons in the claustrum of the rabbit and comparison with the cortex and putamen. Neuroscience Letters, 2000, 282, 177-180.	2.1	24
15	ENVIRONMENTAL IMPACT ASSESSMENT OF A HEALTH TECHNOLOGY: A SCOPING REVIEW. International Journal of Technology Assessment in Health Care, 2018, 34, 317-326.	0.5	24
16	Early identification and assessment of new and emerging health technologies: Actions, progress, and the future direction of an international collaboration—EuroScan. International Journal of Technology Assessment in Health Care, 2008, 24, 518-525.	0.5	22
17	The Life Cycle of Health Technologies. Challenges and Ways Forward. Frontiers in Pharmacology, 2017, 8, 14.	3.5	22
18	Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years. European Journal of Gastroenterology and Hepatology, 2019, 31, 197-204.	1.6	22

#	Article	IF	Citations
19	Scanning the horizon of obsolete technologies: Possible sources for their identification. International Journal of Technology Assessment in Health Care, 2009, 25, 249-254.	0.5	21
20	EARLY AWARENESS AND ALERT SYSTEMS: AN OVERVIEW OF EUROSCAN METHODS. International Journal of Technology Assessment in Health Care, 2012, 28, 301-307.	0.5	21
21	Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a populationâ€based program: A nested caseâ€control study. United European Gastroenterology Journal, 2018, 6, 755-764.	3.8	20
22	Addressing issues in health technology assessment promotion: Motives, enablers, and barriers. International Journal of Technology Assessment in Health Care, 2011, 27, 55-63.	0.5	19
23	The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implementation Science, 2010, 5, 48.	6.9	15
24	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine Hub, 2020, 5, 1-42.	1.2	15
25	GABAergic neurons with AMPA GluR1 and GluR2/3 immunoraactivity in the rat striate cortex. NeuroReport, 1997, 8, 2495-2499.	1.2	14
26	Policies of screening for colorectal cancer in European countries. International Journal of Technology Assessment in Health Care, 2008, 24, 270-276.	0.5	14
27	Analysis of the quality of clinical practice guidelines on established ischemic stroke. International Journal of Technology Assessment in Health Care, 2008, 24, 333-341.	0.5	14
28	Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain. Health and Quality of Life Outcomes, 2020, 18, 140.	2.4	14
29	Evaluating Public Health Interventions: A Neglected Area in Health Technology Assessment. Frontiers in Public Health, 2020, 8, 106.	2.7	12
30	Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?. Biomedicine Hub, 2020, 5, 1-11.	1.2	11
31	Differences in the identification process for new and emerging health technologies: Analysis of the EuroScan database. International Journal of Technology Assessment in Health Care, 2009, 25, 367-373.	0.5	10
32	CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care, 2016, 32, 292-299.	0.5	10
33	GABAergic neurons in the rabbit visual cortex: percentage, layer distribution and cortical projections. Brain Research, 2000, 862, 171-179.	2.2	9
34	Factors related to the participation and detection of lesions in colorectal cancer screening programme-based faecal immunochemical test. European Journal of Public Health, 2018, 28, 1143-1148.	0.3	9
35	Integrating Empirical Analysis and Normative Inquiry in Health Technology Assessment: The Values in Doing Assessments of Health Technologies Approach. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.5	8
36	POST-INTRODUCTION OBSERVATION OF HEALTHCARE TECHNOLOGIES AFTER COVERAGE: THE SPANISH PROPOSAL. International Journal of Technology Assessment in Health Care, 2012, 28, 285-293.	0.5	7

#	Article	IF	CITATIONS
37	THE EVOLUTION OF EARLY AWARENESS AND ALERT METHODS AND SYSTEMS. International Journal of Technology Assessment in Health Care, 2012, 28, 199-200.	0.5	7
38	An evidence-based framework for identifying technologies of no or low-added value (NLVT). International Journal of Technology Assessment in Health Care, 2020, 36, 50-57.	0.5	7
39	The Learning-Adapting-Leveling model: from theory to hypothesis of steps for implementation of basic genome-based evidence in personalized medicine. Personalized Medicine, 2013, 10, 683-701.	1.5	6
40	Q-SEA - a tool for quality assessment of ethics analyses conducted as part of health technology assessments. GMS Health Technology Assessment, 2017, 13, Doc02.	2.2	6
41	STATUS OF DISINVESTMENT INITIATIVES IN LATIN AMERICA: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW AND A QUESTIONNAIRE. International Journal of Technology Assessment in Health Care, 2017, 33, 674-680.	0.5	5
42	A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies. International Journal of Environmental Research and Public Health, 2020, 17, 8001.	2.6	5
43	Toward a common understanding of competencies for health technology assessment: enhancing educational and training programs around the globe. International Journal of Technology Assessment in Health Care, 2021, 37, e29.	0.5	5
44	Disinvestment Activities and Candidates in the Health Technology Assessment Community: An Online Survey. International Journal of Technology Assessment in Health Care, 2019, 35, 189-194.	0.5	4
45	Postlaunch evidence-generation studies for medical devices in Spain: the RedETS approach to integrate real-world evidence into decision making. International Journal of Technology Assessment in Health Care, 2021, 37, e63.	0.5	4
46	QUALITY ASSESSMENT OF ETHICS ANALYSES FOR HEALTH TECHNOLOGY ASSSESSMENT. International Journal of Technology Assessment in Health Care, 2016, 32, 362-369.	0.5	3
47	OP06 Evaluating Public Health Interventions: A Neglected Area In HTA. International Journal of Technology Assessment in Health Care, 2019, 35, 1-1.	0.5	3
48	Nutrition, a health technology that deserves increasing interest among HTA doers. A systematic review. Frontiers in Pharmacology, 2015, 6, 156.	3.5	2
49	Learning and practicing more value-reflective, problem-setting Health Technology Assessment - Experiences and lessons from the VALIDATE project. International Journal of Technology Assessment in Health Care, 0, , 1-19.	0.5	2
50	Biomedical literature search protocols: Consensus statement from the documentation units of the Spanish health technology assessment agencies. International Journal of Technology Assessment in Health Care, 2008, 24, 104-111.	0.5	1
51	Information needs of health technology assessment units and agencies in Spain. International Journal of Technology Assessment in Health Care, 2010, 26, 463-469.	0.5	1
52	Post-Marketing Health Technology Monitoring. The Analysis of an Experience from a Clinical Perspective. Frontiers in Pharmacology, 2011, 2, 45.	3.5	1
53	Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities. Frontiers in Pharmacology, 2016, 7, 34.	3.5	1
54	OP127 Analysis Of The Competencies To Be Acquired In Health Technology Assessment. International Journal of Technology Assessment in Health Care, 2017, 33, 59-59.	0.5	1

#	Article	IF	CITATIONS
	Summary of recommendations and key points of the consensus of Spanish scientific societies (SEPAR,) Tj ETQq1		
55	oxygen therapy with nasal cannulas in adult, pediatric, and neonatal patients with severe acute respiratory failure. Medicina Intensiva (English Edition), 2021, 45, 298-312.	0.2	1
56	Coding Public Health Interventions for Health Technology Assessments: A Pilot Experience With WHO's International Classification of Health Interventions (ICHI). Frontiers in Public Health, 2021, 9, 620637.	2.7	1
57	Prioritization of COVID-19 vaccination. The added value of the "VALIDATE―approach. Health Policy, 2022, , .	3.0	1
58	PHP75 SCANNING THE HORIZON FOR NEW AND EMERGING OMIC TECHNOLOGIES. Value in Health, 2009, 12, A251.	0.3	0
59	Colorectal cancer screening policy in Europe. International Journal of Technology Assessment in Health Care, 2009, 25, 111-112.	0.5	O
60	Public Health Genomics in Spain: The Status of a Non-Existing Reality. Public Health Genomics, 2012, 15, 313-321.	1.0	0
61	PP083—Dabigatran– demonstrates the need for comprehensive approaches to optimise the use of new drugs. Clinical Therapeutics, 2013, 35, e43-e44.	2.5	O
62	Disinvestment Initiatives in Latin American Countries (Lac): a Systematic Literature Review (Slr). Value in Health, 2015, 18, A856.	0.3	0
63	VP70 Structuring The Process Of Innovation Uptake In Tunisia. International Journal of Technology Assessment in Health Care, 2017, 33, 181-182.	0.5	O
64	OP86 Identifying Surgical Procedures Of Low Or No-Added Value In Spain. International Journal of Technology Assessment in Health Care, 2017, 33, 39-40.	0.5	0
65	VP24 The Development Of A Quality Management Tool For Health Technology Assessment Agencies In Spain. International Journal of Technology Assessment in Health Care, 2017, 33, 156-157.	0.5	O
66	PP168 Combination Therapy Versus Intensification Of Statin Monotherapy. International Journal of Technology Assessment in Health Care, 2017, 33, 143-144.	0.5	0
67	OP04 Lessons Learnt When Implementing A Health Technology Assessment Institution In Costa Rica. International Journal of Technology Assessment in Health Care, 2017, 33, 3-4.	0.5	O
68	OP108 Health Intervention Assessment Report Adaptation: Tunisian Experience. International Journal of Technology Assessment in Health Care, 2017, 33, 50-51.	0.5	0
69	VP32 Improving The Efficiency Of Early Awareness For Non-Drugs In Spain. International Journal of Technology Assessment in Health Care, 2017, 33, 162-163.	0.5	O
70	ENVIRONMENTAL IMPACT ASSESSMENT OF A HEALTH TECHNOLOGY: A SCOPING REVIEW – ADDENDUM. International Journal of Technology Assessment in Health Care, 2018, 34, 536-536.	0.5	0
71	OP105 Disinvestment Toolkit: Patients Involvement In Disinvestment Activities. International Journal of Technology Assessment in Health Care, 2018, 34, 39-40.	0.5	O
72	OP177 Identification Of Technologies Of No Or Low Added Value. International Journal of Technology Assessment in Health Care, 2018, 34, 65-65.	0.5	0

#	Article	IF	CITATIONS
73	VP01 A Disinvestment Toolkit: The Prioritization Of Technologies Of No Or Low Added Value. International Journal of Technology Assessment in Health Care, 2018, 34, 159-159.	0.5	О
74	PP20 Challenges In The Health Technology Assessment Of New/Emergent Non-Pharmacological Technologies. International Journal of Technology Assessment in Health Care, 2019, 35, 40-40.	0.5	0
75	Impact of the Colorectal Cancer Screening after 10 years in the Basque Country (Spain). European Journal of Public Health, 2018, 28, .	0.3	o
76	OP523 Towards A Health Technology Assessment Framework For Omics-Technologies: Preliminary Results Of The ExACT project International Journal of Technology Assessment in Health Care, 2020, 36, 13-13.	0.5	0
77	HTA Metro Map: a patient centred model for optimizing the decision making process. GMS Health Innovation and Technologies, 2019, 15, Doc02.	0.5	O
78	OP188 Post-Launch Evidence Generation Studies For Medical Devices In Spain: Integrating Real World Evidence Into Decision-Making. International Journal of Technology Assessment in Health Care, 2021, 37, 4-5.	0.5	0